<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Though the early integration of mesenchymal stem cells (MSCs) into <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e>-associated stroma of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> has been demonstrated, the functional contributions and underlying mechanisms of these cells to <z:e sem="disease" ids="C0598934" disease_type="Neoplastic Process" abbrv="">tumor growth</z:e> and <z:mpath ids='MPATH_177'>angiogenesis</z:mpath> remain to be clarified </plain></SENT>
<SENT sid="1" pm="."><plain>Using a <z:e sem="disease" ids="C1520166" disease_type="Experimental Model of Disease" abbrv="">xenograft model</z:e>, human <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> cells, MSCs, and their cell mixture were introduced to a subcutaneous site of immunodeficient mice </plain></SENT>
<SENT sid="2" pm="."><plain>The <z:e sem="disease" ids="C0598934" disease_type="Neoplastic Process" abbrv="">tumor growth</z:e> rate and <z:mpath ids='MPATH_177'>angiogenesis</z:mpath> of each transplantation was then compared </plain></SENT>
<SENT sid="3" pm="."><plain>We demonstrate that a variety of <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> cells, when mixed with otherwise non-tumorigenic MSCs, increase the <z:e sem="disease" ids="C0598934" disease_type="Neoplastic Process" abbrv="">tumor growth</z:e> rate and <z:mpath ids='MPATH_177'>angiogenesis</z:mpath> more than that when mixed with <z:mp ids='MP_0002038'>carcinoma</z:mp>-associated fibroblasts or <z:mpath ids='MPATH_458'>normal</z:mpath> colonic fibroblasts </plain></SENT>
<SENT sid="4" pm="."><plain>The secretion of interleukin-6 (IL-6) from MSCs increases the secretion of endothelin-1 (ET-1) in <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> cells, which induces the activation of Akt and ERK in endothelial cells, thereby enhancing their capacities for recruitment and <z:mpath ids='MPATH_177'>angiogenesis</z:mpath> to <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> </plain></SENT>
<SENT sid="5" pm="."><plain>The IL-6/ET-1/Akt or ERK pathway of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e>-stroma interaction can be targeted by an antibody against IL-6 or Lentiviral-mediated RNAi against IL-6 in MSCs, by inhibition or knockdown of ET-1 in <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> cells, or by inhibition of ERK and Akt in host endothelial cells </plain></SENT>
<SENT sid="6" pm="."><plain>These demonstrate that attempts to interrupt the interaction of MSCs and <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> cells help to abrogate <z:mpath ids='MPATH_177'>angiogenesis</z:mpath> and inhibit <z:e sem="disease" ids="C0598934" disease_type="Neoplastic Process" abbrv="">tumor growth</z:e> in <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> formed by <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> cells admixed with MSCs </plain></SENT>
<SENT sid="7" pm="."><plain>These data demonstrate that the <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> microenvironment, namely, MSCs-secreted IL-6, may enrich the proangiognic factors secreted by <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> cells to increase <z:mpath ids='MPATH_177'>angiogenesis</z:mpath> and <z:e sem="disease" ids="C0598934" disease_type="Neoplastic Process" abbrv="">tumor growth</z:e> and that targeting this interaction may lead to novel therapeutic and preventive strategies.Oncogene advance online publication, 22 October 2012; doi:10.1038/onc.2012.458 </plain></SENT>
</text></document>